Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Januar 2015 05:30 ET | Quelle: Achaogen, Inc.

Achaogen Announces Plazomicin Granted QIDP Designation by FDA

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
10. November 2014 07:00 ET | Quelle: Achaogen, Inc.

Achaogen Announces Third Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
29. Oktober 2014 05:30 ET | Quelle: Achaogen, Inc.

Achaogen to Present at 2014 Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR)...
17. September 2014 05:30 ET | Quelle: Achaogen, Inc.

Achaogen Announces First Patient Enrollment in a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
11. August 2014 16:15 ET | Quelle: Achaogen, Inc.

Achaogen Announces Second Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
14. Juli 2014 05:30 ET | Quelle: Achaogen, Inc.

Achaogen Appoints Dr. Ian Friedland as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
12. Mai 2014 08:00 ET | Quelle: Achaogen, Inc.

Achaogen Announces First Quarter 2014 Results

SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
07. April 2014 05:30 ET | Quelle: Achaogen, Inc.

Achaogen to Present at 13th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
02. April 2014 05:30 ET | Quelle: Achaogen, Inc.

Achaogen Appoints Chris Boerner to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...
17. März 2014 11:55 ET | Quelle: Achaogen, Inc.

Achaogen Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., March 17, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant...

Vorherige Seite

Nächste Seite